Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of LC-101 (Doxorubicin Liposome) in Ovarian Cancer
NCT03681548Phase 1Completed
- Sponsor
- Ayana Pharma
- Start
- Aug 2018
- Primary completion
- Feb 2019
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pegylated liposomal doxorubicin in ovarian cancer (2 arms), sponsored by Ayana Pharma. Primary endpoints: Maximum Plasma Concentration (Cmax) of Encapsulated and Free Doxorubicin at 15 days, Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUC0-t) of Encapsulated and Free Doxorubicin at 15 days and 1 more. Started Aug 2018; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03681548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03681548.